Abiopharma

🔍 Booth Bruce (Executive)

Company: Kymera Therapeutics, Inc. (KYMR)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Sold 10,658 shares of Common Stock at $108.28 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,402,089.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 7,833 shares of Common Stock at $109.75 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,394,256.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 7,602 shares of Common Stock at $110.67 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,386,654.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 907 shares of Common Stock at $111.2 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,385,747.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Sold 1,688 shares of Common Stock at $108.28 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 464,389.00 | transaction_form_type: 4 | Footnotes: F1, F2, F7
• Sold 1,239 shares of Common Stock at $109.75 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 463,150.00 | transaction_form_type: 4 | Footnotes: F1, F4, F7
• Sold 1,199 shares of Common Stock at $110.67 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 461,951.00 | transaction_form_type: 4 | Footnotes: F1, F5, F7
• Sold 157 shares of Common Stock at $111.2 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 461,794.00 | transaction_form_type: 4 | Footnotes: F1, F6, F7

Footnotes:

• F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (6).
• F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive.
• F7: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
• REMARKS: Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the second of two filings.